| Treatment of triple negative breast cancer (TNBC): current options and future perspectives M De Laurentiis, D Cianniello, R Caputo, B Stanzione, G Arpino, S Cinieri, ... Cancer treatment reviews 36, S80-S86, 2010 | 249 | 2010 |
| Targeting cell cycle in breast cancer: CDK4/6 inhibitors M Piezzo, S Cocco, R Caputo, D Cianniello, GD Gioia, VD Lauro, G Fusco, ... International Journal of Molecular Sciences 21 (18), 6479, 2020 | 99 | 2020 |
| Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives S Cocco, M Piezzo, A Calabrese, D Cianniello, R Caputo, V Di Lauro, ... International journal of molecular sciences 21 (13), 4579, 2020 | 88 | 2020 |
| Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis M Piezzo, P Chiodini, M Riemma, S Cocco, R Caputo, D Cianniello, ... International journal of molecular sciences 21 (17), 6400, 2020 | 70 | 2020 |
| Quality of life in women diagnosed with breast cancer after a 12-month treatment of lifestyle modifications C Montagnese, G Porciello, S Vitale, E Palumbo, A Crispo, M Grimaldi, ... Nutrients 13 (1), 136, 2020 | 63 | 2020 |
| Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial G Porciello, C Montagnese, A Crispo, M Grimaldi, M Libra, S Vitale, ... PLoS One 15 (10), e0239803, 2020 | 55 | 2020 |
| Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results S De Placido, M Giuliano, F Schettini, C Von Arx, G Buono, F Riccardi, ... The Breast 38, 86-91, 2018 | 32 | 2018 |
| Efficacy and safety of T-DM1 in the ‘common-practice’of HER2+ advanced breast cancer setting: a multicenter study A Fabi, M De Laurentiis, M Caruso, E Valle, L Moscetti, D Santini, ... Oncotarget 8 (38), 64481, 2017 | 30 | 2017 |
| Gene expression assay in the management of early breast cancer R Caputo, D Cianniello, A Giordano, M Piezzo, M Riemma, M Trovò, ... Current Medicinal Chemistry 27 (17), 2826-2839, 2020 | 22 | 2020 |
| PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy F Cognetti, R Masetti, A Fabi, G Bianchi, D Santini, A Rognone, G Catania, ... NPJ Breast Cancer 7 (1), 47, 2021 | 18 | 2021 |
| T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study F Schettini, B Conte, G Buono, P De Placido, S Parola, G Griguolo, A Fabi, ... ESMO open 6 (2), 100099, 2021 | 14 | 2021 |
| Uptake of trastuzumab biosimilars for the treatment of HER2-positive breast cancer: a real-world experience from a cancer center M Piezzo, R D’Aniello, I Avallone, B Barba, D Cianniello, S Cocco, ... Pharmaceutics 13 (5), 684, 2021 | 6 | 2021 |
| Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study. G Buono, A Fabi, L Del Mastro, K Cannita, NM La Verde, R Ardito, ... Journal of Clinical Oncology 37 (15_suppl), e12507-e12507, 2019 | 4 | 2019 |
| 105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): biological and clinical activity, and post-surgical approaches S Parola, V Di Lauro, P De Placido, V Forestieri, G Buono, C von Arx, ... Annals of Oncology 33, S172-S173, 2022 | 1 | 2022 |
| Adherence to Mediterranean Diet and Quality of Life in women treated for breast cancer (DEDiCa Study) G Porciello, I Calabrese, C Montagnese, S Vitale, E Palumbo, S Cubisino, ... Nutrition, Metabolism and Cardiovascular Diseases 29 (8), 881-882, 2019 | 1 | 2019 |
| Taxane-based adjuvant therapy for early breast cancer (EBC): A meta-analysis of the predictive effect of ER and HER2 status. M De Laurentiis, C Criscitiello, M Giuliano, A Giordano, D Cianniello, ... Journal of Clinical Oncology 28 (15_suppl), e11025-e11025, 2010 | 1 | 2010 |
| Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis R Caputo, G Buono, M Piezzo, C Martinelli, D Cianniello, A Rizzo, ... Frontiers in Oncology 14, 1362641, 2024 | | 2024 |
| Post-diagnosis serum 25-hydroxyvitamin D concentrations in women treated for breast cancer participating in a lifestyle trial in Italy A Fassio, G Porciello, G Carioli, E Palumbo, S Vitale, A Luongo, ... Reumatismo 76 (1), 2024 | | 2024 |
| 449P Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study C von Arx, A Calabrese, C Martinelli, V Di Lauro, V Grimaldi, ... Annals of Oncology 34, S370, 2023 | | 2023 |
| Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion R Caputo, G Buono, VD Lauro, D Cianniello, CV Arx, M Pensabene, ... Future Oncology 19 (24), 1695-1708, 2023 | | 2023 |
